Product Code: IRTNTR6492
About Ophthalmic Diseases
Ophthalmology is the science of eyes. It is the branch of medicine concerned with the treatment of eye-related diseases and eye defects. Some of the common eye disorders are glaucoma, retinal diseases, conjunctivitis, refractive errors, color blindness, and retinitis. Many of the eye diseases do not show symptoms at early stages. They will be painless with no defect in vision until the disease progresses to an advanced stage. Regular eye checkups must be done to detect the development of any disorder. Proper care and hygiene must be ensured to protect the eyes.
Technavio's analysts forecast the global ophthalmic therapeutic market to grow at a CAGR of 6.53% over the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global ophthalmic therapeutic market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies, OTC drugs, and generics along with the drugs used as off-label for the treatment of ophthalmic disorders such as:
- Glaucoma
- Dry eye syndrome
- Retinal disorders such as diabetic retinopathy, macular edema, RVO, and AMD
Technavio's report, Global Ophthalmic Therapeutic Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of global ophthalmic therapeutic market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
- Actavis
- Bayer
- F. Hoffmann-La Roche
- Merck
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
Other Prominent Vendors
- Acadia Pharmaceuticals
- AC Immune
- Acorn Biomedical
- Acucela
- Advanced Cell Technology
- Aerie Pharmaceuticals
- Alcon
- Alexion Pharmaceuticals
- Alimera Sciences
- Allergan
- Ampio Pharmaceuticals
- Antisense Therapeutics
- Avalanche Biotechnologies
- BCN Peptides
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Carl Zeiss Meditec
- Eleven Biotherapeutics
- Falcon Pharmaceuticals
- Gilead Sciences
- GlaxoSmithKline
- Glycadia
- Icon Bioscience
- iCo Therapeutics
- Inotek Pharmaceuticals
- Intellect Neurosciences
- Isis Pharmaceuticals
- Kowa Group
- Laboratorios Sophia
- Lexicon Pharmaceuticals
- Lpath
- Neurotech Pharma
- NicOx
- Numoda Capital
- OPKO Health
- Ophthotech Corporation
- Ohr Pharmaceutical
- Otsuka Pharmaceutical
- PanOptica
- Parexel International
- Promedior
- pSivida
- Quark Pharmaceuticals
- R-Tech Ueno
- Santen Pharmaceutical
- Seikagaku
- Senju Pharmaceutical
- Shire
- SIFI
- Sirnaomics
- StemCells
- ThromboGenics
- Valeant Pharmaceuticals
Market Driver
- Increase in Prevalence of Eye Diseases
- For a full, detailed list, view our report
Market Challenge
- Lack of Awareness
- For a full, detailed list, view our report
Market Trend
- Strategic Alliances
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
- 03.1. Market Overview
- 03.2. Product Offerings
04. Market Research Methodology
- 04.1. Market Research Process
- 04.2. Research Methodology
05. Introduction
06. Disease Overview
- 06.1. Glaucoma
- 06.1.1. Understanding the Disease
- 06.1.2. Types of Glaucoma
- 06.1.3. Etiology
- 06.1.4. Signs and Symptoms
- 06.1.5. Diagnosis
- 06.1.6. Management
- 06.1.7. Epidemiology
- 06.2. Dry Eye Syndrome
- 06.2.1. Understanding the Disease
- 06.2.2. Types of Dry Eye Syndrome
- 06.2.3. Causes of Dry Eye Syndrome
- 06.2.4. Risk Factors of Dry Eye Syndrome
- 06.2.5. Signs and Symptoms
- 06.2.6. Diagnosis
- 06.2.7. Management
- 06.3. Diabetic Retinopathy
- 06.3.1. Understanding the Disease
- 06.3.2. Etiology
- 06.3.3. Diagnosis
- 06.3.4. Classification
- 06.3.5. Epidemiology
- 06.3.6. Management
- 06.4. RVO
- 06.4.1. Understanding the Disease
- 06.4.2. Types of RVO
- 06.4.3. Etiology
- 06.4.4. Diagnosis
- 06.4.5. Management
- 06.5. AMD
- 06.5.1. Understanding the Disease
- 06.5.2. Stages of AMD
- 06.5.3. Types of AMD
- 06.5.4. Etiology
- 06.5.5. Signs and Symptoms
- 06.5.6. Diagnosis
- 06.5.7. Management
- 06.6. Macular Edema
- 06.6.1. Understanding the Disease
- 06.6.2. Etiology
- 06.6.3. Diagnosis
- 06.6.4. Management
- 06.7. Economic Burden of Ophthalmic Diseases
07. Pipeline Analysis
- 07.1. Pipeline Portfolio: Glaucoma
- 07.1.1. Rhopressa
- 07.1.2. Roclatan
- 07.1.3. Trabodenoson
- 07.1.4. Lomerizine HCl
- 07.1.5. Y-39983
- 07.2. Pipeline Portfolio: Dry Eye Syndrome
- 07.2.1. Lifitegrast
- 07.2.2. OPC-12759E
- 07.2.3. EBI-005
- 07.3. Pipeline Portfolio: Diabetic Retinopathy
- 07.3.1. Squalamine
- 07.3.2. K-115-R/Ripasudil Hydrochloride Hydrate
- 07.4. Pipeline Portfolio: AMD
- 07.4.1. Anecortave Acetate (Suspension)
- 07.4.2. E10030
- 07.4.3. Abicipar
- 07.5. Pipeline Portfolio: RVO
- 07.5.1. TLC399
- 07.5.2. AGN208397
08. Market Landscape
- 08.1. Market Overview
- 08.2. Market Size and Forecast
- 08.3. Five Forces Analysis
09. Market Segmentation by Disease Type
- 09.1. Global Ophthalmic Therapeutics Market by Disease Type
- 09.2. Glaucoma
- 09.3. Dry Eye Syndrome
- 09.4. Retinal Disorders
- 09.4.1. Diabetic Retinopathy
- 09.4.2. Macular Edema
- 09.4.3. AMD
- 09.4.4. RVO
- 09.5. Global Glaucoma Therapeutics Market
- 09.5.1. Market Size and Forecast
- 09.6. Global AMD Therapeutics Market
- 09.6.1. Market Size and Forecast
- 09.7. Global Macular Edema Therapeutics Market
- 09.7.1. Market Size and Forecast
- 09.8. Global Dry Eye Syndrome Therapeutics Market
- 09.8.1. Market Size and Forecast
- 09.9. Global Diabetic Retinopathy Therapeutics Market
- 09.9.1. Market Size and Forecast
- 09.10. Global RVO Therapeutics Market
- 09.10.1. Market Size and Forecast
10. Market Segmentation by Route of Administration
- 10.1. Topical
- 10.2. Systemic
- 10.3. Intravitreal
11. Market Segmentation by Molecule Type
- 11.1. Biologics
- 11.2. Small Molecules
12. Market Segmentation by Dosage Form
- 12.1. Solutions
- 12.2. Implants
- 12.3. Pills
13. Geographical Segmentation
- 13.1. Global Ophthalmic Therapeutics Market by Geography 2014-2019
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and Their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and Their Impact
21. Vendor Landscape
- 21.1. Competitive Scenario
- 21.1.1. Key News
- 21.1.2. Mergers and Acquisitions
- 21.2. Market Share Analysis 2014
- 21.2.1. Novartis
- 21.2.2. Actavis
- 21.2.3. F. Hoffmann-La Roche
- 21.2.4. Regeneron Pharmaceuticals
- 21.2.5. Bayer
- 21.2.6. Pfizer
- 21.2.7. Merck
- 21.3. Other and Future Prominent Vendors
22. Key Vendor Analysis
- 22.1. Actavis
- 22.1.1. Key Facts
- 22.1.2. Business Description
- 22.1.3. Business Segmentation
- 22.1.4. Business Segmentation by Revenue 2012 and 2013
- 22.1.5. Sales by Geography
- 22.1.6. Business Strategy
- 22.1.7. Key Information
- 22.1.8. SWOT Analysis
- 22.2. Bayer
- 22.2.1. Key Facts
- 22.2.2. Business Overview
- 22.2.3. Business Segmentation by Revenue 2014
- 22.2.4. Business Segmentation by Revenue 2013 and 2014
- 22.2.5. Geographical Segmentation by Revenue 2014
- 22.2.6. Business Strategy
- 22.2.7. Recent Developments
- 22.2.8. SWOT Analysis
- 22.3. F. Hoffmann-La Roche
- 22.3.1. Key Facts
- 22.3.2. Business Overview
- 22.3.3. Business Segmentation
- 22.3.4. Business Segmentation by Revenue 2012 and 2013
- 22.3.5. Sales by Geography
- 22.3.6. Business Strategy
- 22.3.7. Key Information
- 22.3.8. SWOT Analysis
- 22.4. Merck
- 22.4.1. Key Facts
- 22.4.2. Business Overview
- 22.4.3. Business Segmentation by Revenue 2013
- 22.4.4. Business Segmentation by Revenue 2012 and 2013
- 22.4.5. Sales by Geography
- 22.4.6. Business Strategy
- 22.4.7. Key Developments
- 22.4.8. SWOT Analysis
- 22.5. Novartis
- 22.5.1. Key Facts
- 22.5.2. Business Description
- 22.5.3. Business Segmentation
- 22.5.4. Revenue by Business Segmentation
- 22.5.5. Revenue Comparison 2012 and 2013
- 22.5.6. Sales by Geography
- 22.5.7. Business Strategy
- 22.5.8. Key Developments
- 22.5.9. SWOT Analysis
- 22.6. Pfizer
- 22.6.1. Key Facts
- 22.6.2. Business Overview
- 22.6.3. Business Segmentation by Revenue 2014
- 22.6.4. Business Segmentation by Revenue 2013 and 2014
- 22.6.5. Geographical Segmentation by Revenue 2014
- 22.6.6. Business Strategy
- 22.6.7. Key developments
- 22.6.8. SWOT Analysis
- 22.7. Regeneron Pharmaceuticals
- 22.7.1. Key Facts
- 22.7.2. Business Overview
- 22.7.3. Product Segmentation
- 22.7.4. Revenue Product Segmentation
- 22.7.5. Business Strategy
- 22.7.6. Key Information
- 22.7.7. SWOT Analysis
23. Other Reports in This Series
List of Exhibits
- Exhibit 1: Market Research Methodology
- Exhibit 2: Major Ophthalmic Conditions
- Exhibit 3: Types of Glaucoma
- Exhibit 4: Development of Diabetic Retinopathy
- Exhibit 5: Classification of Diabetic Retinopathy
- Exhibit 6: Types of RVO
- Exhibit 7: Types of AMD
- Exhibit 8: Global Ophthalmic Therapeutics Market 2014-2019 ($ millions)
- Exhibit 9: Global Ophthalmic Therapeutics Market by Disease Type
- Exhibit 10: Global Ophthalmic Therapeutics Market by Disease Type 2014
- Exhibit 11: Global Glaucoma Therapeutics Market 2014-2019 ($ millions)
- Exhibit 12: Key Takeaways: Global Glaucoma Therapeutics Market
- Exhibit 13: Global AMD Therapeutics Market 2014-2019 ($ millions)
- Exhibit 14: Key Takeaways: Global AMD Therapeutics Market
- Exhibit 15: Global Macular Edema Therapeutics Market 2014-2019 ($ millions)
- Exhibit 16: Key Takeaways: Global Macular Edema Therapeutics Market
- Exhibit 17: Global Dry Eye Syndrome Therapeutics Market 2014-2019 ($ millions)
- Exhibit 18: Key Takeaways: Global Dry Eye Syndrome Therapeutics Market
- Exhibit 19: Global Diabetic Retinopathy Therapeutics Market 2014-2019 ($ millions)
- Exhibit 20: Key Takeaways: Global Diabetic Retinopathy Therapeutics Market
- Exhibit 21: Global RVO Therapeutics Market 2014-2019 ($ millions)
- Exhibit 22: Key Takeaways: Global RVO Therapeutics Market
- Exhibit 23: Global Ophthalmic Therapeutics Market: YoY Growth Rate and Revenue by Disease Type 2014-2019
- Exhibit 24: Global Ophthalmic Therapeutics Market by Route of Administration
- Exhibit 25: Global Ophthalmic Therapeutics Market by Molecule Type
- Exhibit 26: Global Ophthalmic Therapeutics Market by Dosage Form
- Exhibit 27: Global Ophthalmic Therapeutics Market by Geography 2014
- Exhibit 28: Major Drivers of Global Ophthalmic Therapeutics Market
- Exhibit 29: Major Challenges in Global Ophthalmic Therapeutics Market
- Exhibit 30: Major Trends in Global Ophthalmic Therapeutics Market
- Exhibit 31: Vendor Ranking 2014
- Exhibit 32: Novartis: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
- Exhibit 33: Actavis: YoY Revenue of Restasis 2012-2014 ($ millions)
- Exhibit 34: Actavis: YoY Revenue of Lumigan 2012-2014 ($ millions)
- Exhibit 35: Actavis: YoY Revenue of Alphagan, Alphagan P, and Combigan 2012-2014 ($ millions)
- Exhibit 36: F. Hoffmann-La Roche: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
- Exhibit 37: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate of Eylea 2011-2014 ($ millions)
- Exhibit 38: Bayer: YoY Revenue and Growth Rate of Eylea 2012-2014 ($ millions)
- Exhibit 39: Pfizer: YoY Revenue and Growth Rate of Xalatan/Xalacom 2012-2014 ($ millions)
- Exhibit 40: Actavis: Business Segmentation 2013
- Exhibit 41: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ millions)
- Exhibit 42: Actavis: Sales by Geography ($ millions)
- Exhibit 43: Bayer: Business Segmentation by Revenue 2014
- Exhibit 44: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
- Exhibit 45: Bayer: Geographical Segmentation by Revenue 2014
- Exhibit 46: Business Segmentation of F. Hoffmann-La Roche 2013
- Exhibit 47: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
- Exhibit 48: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
- Exhibit 49: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
- Exhibit 50: Merck: Business Segmentation by Revenue 2013
- Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
- Exhibit 52: Merck: Sales by Geography 2013
- Exhibit 53: Novartis: Business Segmentation
- Exhibit 54: Novartis: Revenue by Business Segmentation 2013
- Exhibit 55: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
- Exhibit 56: Novartis: Revenue by Geographical Segmentation 2013
- Exhibit 57: Pfizer: Business Segmentation by Revenue 2014
- Exhibit 58: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
- Exhibit 59: Pfizer: Geographical Segmentation by Revenue 2014
- Exhibit 60: Regeneron Pharmaceuticals: Product Segmentation
- Exhibit 61: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
